FDA Approves Psychedelic Magic Mushrooms Ingredient Psilocybin for Depression Trial Newsweek
The Food and Drug Administration has approved the use of the psychedelic ingredient in magic mushrooms for a drug trial for treatment-resistant depression.
Plant and Drug Research Studies
FDA Approves Psychedelic Magic Mushrooms Ingredient Psilocybin for Depression Trial Newsweek
The Food and Drug Administration has approved the use of the psychedelic ingredient in magic mushrooms for a drug trial for treatment-resistant depression.
Ayahuasca active ingredient DMT mimics near-death experience Business Insider
The psychedelic drug ayahuasca, which originates in the Amazon, has become popular in the US in recent years, with Silicon Valley entrepreneurs flying to …
Historic Hurricane Lane poses grave threat to Hawaii Axios
Hurricane Lane has come closer to Hawaii than any Category 5 storm has come in modern records, and it threatens to unleash life-threatening destruction as it …
Magic mushrooms might treat depression? Peter Thiel-backed Compass gets FDA OK to launch Phase IIb trials Endpoints News
For years now, psychedelic scientists have been telling us that tripping on magic mushrooms might “reboot” the brain, clearing out negative thought networks …
How Peddlers of Food Grade Hydrogen Peroxide Exploit the Sick Undark Magazine
Hucksters claim that drinking a few drops of hydrogen peroxide diluted in a glass of water will cure almost anything. How do they get away with it?
Psychedelic compound triggers near-death experiences Medical News Today
A new study, published in the journal Frontiers in Psychology, suggests that a psychedelic compound found in ayahuasca replicates near-death experiences in …
New on the Black Market: Vape Pens Full of DMT TheStranger.com
Is vaping the most powerful psychedelic in the world a good idea? Only one way to find out.
Why taking ayahuasca is like having a near-death experience New Scientist News
A psychedelic drug produces effects similar to near-death experiences. The finding suggests changes to brain activity may explain such paranormal …
Enrollment Reached in Phase 3 Trials to Test Ublituximab in Relapsing MS Multiple Sclerosis News Today
TG Therapeutics announced it has reached target enrollment in the ULTIMATE I and II Phase 3 clinical trials assessing the use of ublituximab (TG-1101) to treat …
Psychedelic Drugs Show Promise for Treating Anxiety, Depression, PTSD PsychCentral.com
New findings add to the growing body of evidence suggesting that psychedelic drugs may be effective at treating a variety of psychological disorders, including.